Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Arguedas et al. conducted a Phase II pilot study that compared the safety and efficacy of single dose azithromycin with 3-day azithromycin or single dose intramuscular ceftriaxone.